Cited by 49Hormonal and reproductive studiesMenopause: Health Impacts and TreatmentsAdrenal Hormones and Disorders

Effects of intermission and resumption of long‐term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middle‐aged and elderly men

Open access
Yassin, Aksam, Almehmadi, Yousef, Saad, Farid, Doros, Gheorghe, Gooren, Louis·2016·Clinical Endocrinology

Abstract

Summary: Objective: In addition to primary and secondary (‘classical’) hypogonadism, hypogonadism occurring in middle‐aged and elderly men has been recognized. There is evidence that restoring T levels to normal improves body weight, serum lipids and glucose levels. Design: Observational registry study. Patients: Two hundred and sixty‐two hypogonadal, middle‐aged and elderly, men received testosterone replacement treatment (TRT). After having been on TRT for a mean duration of 65·5 months, TRT was temporarily intermitted in 147 patients for a mean of 16·9 months (Group I) due to cost reimbursement issues and in seven men due to prostate cancer. All these men resumed TRT for a mean period of 14·5 months. Of the cohort, 115 men were treated continuously (designated as Group C). To compare on‐treatment to off‐treatment periods, three periods of equal duration were defined: pre‐intermission (on TRT), during intermission (off TRT) and post‐intermission (on TRT after resumption of TRT). For proper comparison, the same periods were analysed for those patients who continued TRT throughout (Group C). Measurements: Variables of body weight, glucose metabolism, lipids, blood pressure and C‐reactive protein (CRP). Results: In Group C there was a continuous improvement of body weight, serum lipids, glucose, HbA 1c, blood pressure and CRP. In Group I there was a similar initial improvement which was reversed upon intermission of T administration but which appeared again when T treatment was reinstated. Conclusions: Our observation indicates that T administration improves body weight and metabolic factors in men with hypogonadism but withdrawal of T reverses these beneficial effects to appear again when TRT is resumed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/cen.12936

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Testosterone treatment needs to be given long term to maintain benefits.

    “This suggests, consistent with other studies, 103,104 that testosterone treatment needs to be given long term to maintain benefits.”

    From Hypogonadism and male obesity: Focus on unresolved questions (2018) · cites this paper as [104]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. Muraleedharan, V. & Jones, T.H. (2014) Testosterone and mor- tality. Clinical Endocrinology (Oxford), 81, 477-487.

Cited by

Sorted by citations

Authors
Yassin, A., Almehmadi, Y., Saad, F., Doros, G., & Gooren, L.
Affiliations
  • Gulf Medical University (AE)
  • Boston University (US)
  • Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
Corresponding author
Saad, Farid
Venue
Clinical Endocrinology
Publisher
Wiley
Published
2015-10-02
Volume
84
Issue
1
Pages
107-114
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W1862607539
Cited by
49
References
25
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2023: 4 · 2022: 4 · 2021: 3 · 2020: 7 · 2019: 4 · 2018: 6 · 2017: 7 · 2016: 7 · 2015: 2
FWCI
6.38
Type
journal article
Language
en
Open access
Locations
  • Clinical Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
testosterone replacement therapy, hypogonadism, middle-aged men, older men, body weight, serum lipids, glucose metabolism, HbA1c, blood pressure, C-reactive protein, cost reimbursement
MeSH terms
Adult, Aged, Androgens, Blood Glucose, Body Weight, C-Reactive Protein, Humans, Hypogonadism, Lipids, Male, Middle Aged, Testosterone, Cohort Studies, Outcome Assessment, Health Care, Hormone Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review